A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation

(2022) Kenta Haraya et al.   Pharmaceuticals

The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

(2021) Tore K. Kvien et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity

(2016) Sihem Ait-Oudhia et al.   mAbs

The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review

(2014) Winnie Sohn et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Biologics: An Update and Challenge of Their Pharmacokinetics

(2014) Shaojun Shi   CURRENT DRUG METABOLISM

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

(2010) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE